MediciNova, Inc. provided an update on the enrollment progress of two key ongoing clinical trials for its developmental compounds, MN-166 (ibudilast) and MN-001 (tipelukast). Both trials are poised to complete randomization, indicating significant advancement.
The company is now down to single-digit required randomization in its Phase 2/3 COMBAT-ALS trial for MN-166. Concurrently, MediciNova is seeking the final two randomized subjects for its Phase 2 trial of MN-001 in patients with dyslipidemia and fatty liver disease due to type 2 diabetes.
Dr. Yuichi Iwaki, MediciNova President and CEO, stated that the large NIH-funded Expanded Access Program (EAP) for MN-166 is steadily enrolling patients. Top-line data for the MN-166 ALS program is anticipated by the end of next year, and the company is actively preparing for regulatory discussions with the FDA.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.